ImmuCell Corporation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
ImmuCell Corporation (ICCC) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $52.87 thousand as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $52.87K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $82.37K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $50.72K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $23.37K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2025-12-31 | $52.87K 10-K · filed 2026-03-30 |
| 2024-12-31 | $82.37K 10-K · filed 2026-03-30 |
| 2023-12-31 | $50.72K 10-K · filed 2025-03-28 |
| 2022-12-31 | $23.37K 10-K · filed 2024-04-01 |
| 2022-03-31 | $222.00K 10-Q/A · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |